Moderna Inc (MRNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $87.10B
Last updated: Nov 17, 2026 at 4:55 PM ET
Moderna Inc (MRNA) Statistics
Moderna (MRNA) has a market cap of $87.10B and an enterprise value of $89.46B. It kept -110.46% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 2.70% above the market cap, as debt exceeds cash.
| Market Cap | $87.10B |
|---|---|
| Enterprise Value | $89.46B |
| Latest price (Nov 17, 2026) | $206.80 |
Key Dates
The next earnings report is expected on Feb 11, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 11, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 32.8x and 12.1x. Its year-end P/S ranged from 3.7x to 107.8x from 2018 to 2025.
| P/S Ratio | 32.8x |
|---|---|
| Forward P/S | 36.1x |
| P/B Ratio | 12.1x |
Price Statistics
The stock is up 734.88% over 52 weeks and trades 1.18% above its 50-day average.
| Beta (1Y) | 2.32 |
|---|---|
| 52-Week Change | +734.88% |
| 1-Month Change | -8.85% |
| 3-Month Change | +18.59% |
| 6-Month Change | +352.32% |
| 5-Year Change | -35.77% |
| Total Return (1Y) | +734.88% |
| Total Return (3Y CAGR) | +39.33% |
| Total Return (5Y CAGR) | -3.83% |
| Return vs SPY (1Y) | +718.30% |
| Max Drawdown (1Y) | -34.16% |
| Max Drawdown (3Y) | -86.58% |
| Sharpe Ratio (1Y) | 1.63 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $204.39 |
| 200-Day Average | $98.09 |
| 52-Week Range | $22.28 to $280.80 |
| RSI (14 Days) | 44.4 |
| Average Volume (20 Days) | 13.83M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.62x current liabilities, and total debt is 0.52x shareholder equity.
| Current Ratio | 3.62x |
|---|---|
| Quick Ratio | 3.47x |
| Debt / Equity | 0.52x |
Returns and Efficiency
Return on invested capital is -28.89% over the last 12 months, against a 5-year average of -33.36%.
| Return on Equity (ROE) | -40.79% |
|---|---|
| Return on Assets (ROA) | -20.71% |
| Return on Invested Capital (ROIC) | -28.89% |
| ROE (5Y Average) | 6.13% |
| ROA (5Y Average) | 1.63% |
| ROIC (5Y Average) | -33.36% |
| Asset Turnover | 0.20x |
| Inventory Turnover | 6.13x |
| Receivables Turnover | 3.65x |
| Cash Conversion Cycle | 117 days |
Scores
MRNA has an Altman Z-Score of 7.98, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.98 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $2.52B over the last 12 months is up 13.13% from the 12 months before.
| Revenue | $2.52B |
|---|---|
| Revenue Growth (YoY) | +13.13% |
| Gross Profit | $707.00M |
| Operating Income | -$2.93B |
| Pretax Income | -$2.73B |
| Net Income | -$2.79B |
| Reported EPS (TTM) | -$7.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 50.78% of the $13.47B in total assets.
| Cash and Equivalents | $1.20B |
|---|---|
| Total Debt | $3.55B |
| Net Debt | $2.35B |
| Net Debt Per Share | $5.87 |
| Working Capital | $5.32B |
| Shareholder Equity | $6.84B |
| Book Value Per Share | $17.05 |
| Total Assets | $13.47B |
| Total Liabilities | $6.63B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $185.00M of capital spending, operating cash flow left -$1.97B of free cash flow.
| Operating Cash Flow | -$1.78B |
|---|---|
| Capital Expenditures | $185.00M |
| Free Cash Flow | -$1.97B |
| FCF Per Share | -$4.93 |
| Depreciation and Amortization | $303.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -116.04%, against a 5-year average of -44.21%.
| Gross Margin | 28.00% |
|---|---|
| Operating Margin | -116.04% |
| Pretax Margin | -108.08% |
| Net Margin | -110.46% |
| FCF Margin | -78.02% |
| Gross Margin (5Y Average) | 59.86% |
| Operating Margin (5Y Average) | -44.21% |
| Net Margin (5Y Average) | -42.92% |
Growth
Revenue fell 53.44% a year over 3 years.
| Revenue Growth (3Y CAGR) | -53.44% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.34% |
| Book Value Per Share Growth (2Y CAGR) | -20.68% |
| Tangible Book Per Share Growth (2Y CAGR) | -20.68% |
Dividends and Yields
MRNA does not pay a dividend. Its free cash flow yield is -2.38%.
| FCF Yield | -2.38% |
|---|---|
| Buyback Yield | -0.23% |
| Shareholder Yield | -0.23% |
Peer Position
Against 12 similar companies, MRNA has the 3rd highest P/S.
P/S RatioPeer median 11.1x
ROICPeer median 6.17%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +18.59%
| P/S Ratio | 32.8x vs 11.1x median |
|---|---|
| ROIC | -28.89% vs 6.17% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.13% vs +18.59% median |
Analyst Forecast
Consensus estimates put revenue growth at 16.28% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +16.28% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRNA
What is MRNA's market cap?
Moderna has a market cap of $87.10B. Its enterprise value, which adds debt and subtracts cash, is $89.46B.
How many shares of MRNA are outstanding?
Moderna has 401.00M shares outstanding. The count is up 2.82% from a year earlier.
Does MRNA pay a dividend?
No. Moderna does not pay a dividend.
How much debt does MRNA have?
Moderna has $3.55B of total debt and $1.20B of cash and equivalents, a net debt position of $2.35B.
MRNA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors